CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES
California Cancer Reporting System Standards, Volume I

Changes and Clarifications –21st Edition
January 29, 2021

Quick Look - Updates to Volume I

New Data Items

VOL I Section #	Data Item	Requirement
III.2.1.1	Name--Birth Surname	Required
IV.3.1	NCDB--SARSCoV2--Test	Required, when available, DX Years 2020 - 2021
IV.3.2	NCDB--SARSCoV2--Pos	Required, when available, DX Years 2020 - 2021
IV.3.3	NCDB--SARSCoV2--Pos Date	Required, when available, DX Years 2020 - 2021
IV.3.4	NCDB--COVID19--Tx Impact	Required, when available, DX Years 2020 - 2021
V.10.1	AJCC TNM Post Therapy Clin (yc) T	Required, CoC Only
V.10.1	AJCC TNM Post Therapy Clin (yc) T Suffix	Required, CoC Only
V.10.1	AJCC TNM Post Therapy Clin (yc) N	Required, CoC Only
V.10.1	AJCC TNM Post Therapy Clin (yc) N Suffix	Required, CoC Only
V.10.1	AJCC TNM Post Therapy Clin (yc) M	Required, CoC Only
V.10.1	AJCC TNM Post Therapy Clin (yc) Stage Group	Required, CoC Only
V.4.1.3	Grade Post Therapy Clin (yc)	Required, Site Specific
VI.1.3.1	Neoadjuvant Therapy	Required
VI.1.3.2	Neoadjuvant Therapy-Clinical Response	Required
VI.1.3.3	Neoadjuvant Therapy-Treatment Effect	Required
Appendix Q	ALK Rearrangement	Required
Appendix Q	EGFR Mutational Analysis	Required
Appendix Q	BRAF Mutational Analysis	Required
Appendix Q	NRAS Mutational Analysis	Required
Appendix Q	CA 19-9 PreTX Lab Value	Required

Other New Sections/Pages Added

VOL I Section #	Volume I Topic	Reason for Addition
IV.3	COVID-19	Introduction to COVID-19 data items
VI.3.1	NCDB--SARSCoV2--Test	Instruction page for new NCDB--SARSCoV2--Test
VI.3.2	NCDB--SARSCoV2--Pos	Instruction page for new NCDB--SARSCoV2--Pos
VI.3.3	NCDB--SARSCoV2--Pos Date	Instruction page for new NCDB--SARSCoV2--Pos Date
VI.3.4	NCDB--COVID19--Tx Impact	Instruction page for new NCDB-- COVID19--Tx Impact
V.4.1.3	Grade Post Therapy Clin (yc)	Separated Clin (yc) into a separate page
VI.1.3	Neoadjuvant Treatment - First Course of Treatment	Introduction page for new Neoadjuvant Treatment data items
VI.1.3.1	Neoadjuvant Therapy	New 2021 Data Item
VI.1.3.2	Neoadjuvant Therapy - Clinical Response	New 2021 Data Item
VI.1.3.3	Neoadjuvant Therapy - Treatment Effect	New 2021 Data Item
VII.2.11.1	Date of First Recurrence Flag	Page added for consistency of date/flag data items
VII.2.11.2	Type of First Recurrence	Page added to separate date and type instructions

Section/Page Revisions

VOL I Section #	Data Item or Volume I Topic	Reason for Revision
I.1.2	The California Cancer Registry	Updated statistics for SEER coverage area 2020
I.1.6	Reporting	Added outpatient blood draw to non-reportable list
I.1.6.4	Date Format and Date Flag Guide Page	Added Date of First Recurrence Flag to linked PDF
II.1	CCR Reportability Guide - Reportable	2021 requirements
II.1.1	CCR Reportability Guide - Non-Reportable or Historically Reportable	2021 requirements
II.2	Determining Reportability	Added ICD-O-3.2, coding instructions
II.2.2	Ambiguous Diagnostic Reportable Terms	Updated guideline to ICD-O-3.2
II.2.5	Benign/Borderline Brain and CNS Tumors	Added coding instruction and exception
II.2.5.1	Date of Diagnosis for Benign/Borderline Brain and CNS Tumors	Added instruction
II.2.5.3	WHO Grade - Benign/Borderline Brain and CNS Tumors	Reordered; Added coding instruction
II.3	Abstracting - Accession and Sequence Number	Added clarification to description
III.2.1	Name	Replaced Maiden Name with Birth Surname
III.2.1.1	Entering Names	Replaced Maiden Name with Birth Surname
III.2.2	Medical Record Number	Removed alternative medical record number instructions
III.2.8	Sex	Added priority order for codes 5 and 6
III.2.10	Race and Ethnicity	Added instruction
III.2.10.1	Codes for Race Data Item	Renamed page
III.2.10.2	Spanish/Hispanic Origin	Added Birth Surname
III.2.12	Age at Diagnosis	Updated description
III.3.3	Date of Diagnosis	Added instruction
III.3.9	Payment Source (Primary and Secondary) and Payment Source Text	Added instructions; Updated code 60
III.3.16	Discovered by Screening	Separated description and coding instruction
IV.1.6	Text - Pathology Findings	Added priority order
IV.2	Diagnostic Confirmation	Clarified priority order; Added/updated multiple instructions
V.1	Primary Site	Added ICD-O-3; Updated multiple instructions
V.3.1	Primary Site - Site-Specific Special Conditions	Added/updated multiple instructions
V.3	ICD-O Morphology - Histology and Behavior	Added ICD-O-3.2
VI.3.1	Histologic Type	Added ICD-O-3.2
V.3.3	Behavior	Updated example
V.4	Grade and Differentiation	2021 Requirements; Clarification added
V.4.1	Grade - General Information	2021 Requirements
V.4.1.1	Grade - Clinical	2021 Requirements; Clarification added
V.4.1.2	Grade - Pathological	2021 Requirements; Clarification added
V.4.1.4	Grade - Post Therapy Path (yp)	Changed Section # and Name; Clarification added; Update to code 9 instruction
V.5.1	Tumor Size Clinical	Added priority; Added/updated multiple instructions
V.5.2	Tumor Size Pathologic	Added priority; Added/updated multiple instructions
V.5.3	Tumor Size Summary	Added priority; Added/updated multiple instructions
V.6	Mets at Diagnosis Bone, Brain, Liver, Lung, Distant Lymph Nodes, and Other	Removed lymphoma histology codes instruction
V.6.1	Mets at Diagnosis - Bone	Revised Codes 0 and 8; Clarified sites coded to 8
V.6.2	Mets at Diagnosis - Brain	Revised Codes 0 and 8; Clarified sites coded to 8
V.6.3	Mets at Diagnosis - Liver	Revised Codes 0 and 8; Clarified sites coded to 8
V.6.4	Mets at Diagnosis - Lung	Revised Codes 0 and 8; Clarified sites coded to 8

VI.9	RX Summary - Treatment Status	Added/Updated coding instructions
VII.2.11	Date of First Recurrence	Renamed; Separated date and type into two pages
IX.1.2	Modified Record	Updated link to Volume II, Appendix A instead of B
Appendix A	Terms and Definitions	Added terms and definitions
Appendix C	Codes for Countries	Updated and reordered terms and codes
Appendix G	Casefinding Lists	Updated lists
Appendix H	Codes for California Counties	Reformatted table and added Region
Appendix K	STORE Surgery Codes	General and site-specific updates
Appendix Q	Site-Specific Data Items (SSDIs)	Added 2021 data items; Name changes; added stage related SSDIs tables.
Appendix R	Coding Resources	Added/Updated Manuals and publication dates
Appendix S	Historical Coding and Staging Manual Requirements for CCR	Added manuals that are now historical.

Items No Longer Required/Pages Deleted

VOL I Section # HISTORICAL NOW)	Data Item	Requirement
VI.3.6	Radiation - Regional RX Modality	*Not required for cases diagnosed January 1, 2018 forward.* The Radiation Treatment Phase I-III data items replaced this in 2018.
VI.3.7	Radiation - RX Summ Radiation	*Not required for cases diagnosed January 1, 2018 forward.* The Radiation Treatment Phase I-III data items replaced this in 2018.

Other Sections/Pages Deleted

VOL I Section # (HISTORICAL NOW)	Volume I Topic	Reason for Deletion
V.10.1.1	AJCC TNM Clinical	Replaced by adding link from V.10.1 to STORE Manual
V.10.1.2	AJCC TNM Pathological	Replaced by adding link from V.10.1 to STORE Manual
V.10.1.3	AJCC TNM Post Therapy	Replaced by adding link from V.10.1 to STORE Manual

*See Archived Volume I - Use case year of diagnosis to determine which volume I to choose.

GENERAL CHANGES

Volume I is only presented in PDF format. The web version and self-extracting versions were no longer presented after the 2017 data changes. For historical Volumes, see Archived Volume I - Use case year of diagnosis to determine which Volume I to choose.

All Pages:
- ✓ Updated and confirmed internal and external links throughout the document.
- ✓ Removed decimal from site code throughout the document for consistency.
- ✓ Formatting, grammar, and editing for typos done throughout the document.
- ✓ Many formatting changes to Volume I and **all** accompanying appendices have been updated. These changes include text color, font size, and table structure have been implemented in order to become ADA compliant.

Select Pages:
- ✓ Updated the term "field" to "data item" to stay consistent with standard setter's.
- ✓ Changed "Other Ill-Defined" to "Ill-Defined Other" to stay consistent with standard setter's.
- ✓ References to "melanoma of skin and breast cases" updated to "breast and cutaneous melanoma cases."
- ✓ Updated "ICD-O-3" to "ICD-O-3.2"
- ✓ Updated histology for Hematopoietic and lymphoid neoplasms from 9992/3 to 9993/3.
- ✓ Updated dates for examples to more current dates.
- ✓ Updated site-histology lists to list Schema ID/Schema Name where appropriate.
- ✓ There are pages that have been renumbered/reordered in order to fit new topics for 2021 data items.
- ✓ New items and/or revisions will not be highlighted in yellow this year in order to remain ADA compliant.

SECTION CHANGES

I.I.2 The California Cancer Registry
- ✓ Updated the statistics for SEER coverage area based on 2020 US population.
- ✓ Updated number of regions based on the SEER website.
- ✓ Updated the California population with value for 2020.

I.1.6 Reporting
- ✓ Added outpatient blood draw to the Cases not Reportable list.

I.1.6.4 Date Format and Date Flag Guide
- ✓ Updated PDF - Date Format and Date Flag Guide to include Date of First Recurrence Flag.

II.1 CCR Reportability Guide - Reportable
- ✓ Added important 2021 ICD-O-3.2 histology coding changes and reminders to this page.
- ✓ Added site and/or histology codes.
- ✓ Moved Urine cytology from II.1.1. Urine cytology is reportable.
  - ➢ Added note: Code to C689 in the absence of any other information.
- ✓ Added the following reportable terms for 2021.
  - ➢ ***Appendix** (C181)
    - ▪ Correction made to change to Carcinoid Tumors, NOS 8240 **with malignant behavior /3**, **dx 01/01/2015** + (from Carcinoid Tumors, NOS) to align with standard setters.
  - ➢ **Gastrointestinal stromal tumors (GIST):**
    - ▪ **ALL GIST tumors are reportable with a malignant behavior /3 in ICD-O-3.2**, 8936/3, dx 01/01/2021 +
  - ➢ **Skin** (C440-C449)
    - ▪ **Early or evolving melanoma of any type IS reportable prior to 01/01/2018 and became reportable again, dx 01/01/2021 +**
      Note: This includes both invasive and in-situ melanomas; early or evolving are **not** reportable.
  - ➢ **Thymoma** (C379)
    - ▪ Nearly all thymomas are reportable, behavior /3 in ICD-O-3.2, dx 01/01/2021 +

Exceptions:
- Microscopic thymoma or thymoma, benign, 8580/0.
- Micronodular thymoma with lymphoid stroma, 8580/1.
- Ectopic hamartomatous thymoma, 8587/0.

✓ Other updates:
  ➢ **Liver** (C220)
    ▪ Report liver cases stated LR-4 or LR-5 based on the [American College of Radiology Liver Imaging Reporting and Data System (LI-RADS)](#) definitions.
  ➢ **Prostate** (C61.9)
    ▪ Report prostate cases stated LR-4 or LR-5 based on the [American College of Radiology Prostate Imaging Reporting and Data System (PI-RADS)](#) definitions.
  ➢ ***Urine Cytology** - Positive for malignancy, dx 01/01/2013 +

*Represents Correction to reportability in Volume I, based on review of the SEER Program Manual. Registries are not required make changes to previous year cases based on this information.

II.1.1 CCR Reportability Guide - Non-Reportable or Historically Reportable
✓ Updated Liver from LR-4 to LR3.
✓ Moved Urine Cytology to II.1, Urine cytology is reportable.
✓ Added Prostate PIN III to non-reportable list.
✓ The following updates made based on 2021 reporting changes:
  ➢ **Gastrointestinal stromal tumors (GIST)**
    ▪ Prior to dx 01/01/2021, GIST was reportable when:
      • Documented as being in-situ.
      • Documented as NOS with multiple foci, lymph node involvement, or metastasis.
      • Patient undergoing treatment as if it is malignant.
  ➢ **Skin** (C440-C449) histologies 8000-8110, has always been non-reportable.
    ▪ **Early or evolving melanoma of any type was <u>not</u> reportable if diagnosed between 01/01/2018 - 12/31/2020.**
  ➢ **Thymoma** (C379)
    ▪ Prior to dx 01/01/2021 thymoma's were reportable when:
      • Documented as NOS with multiple foci, lymph node involvement, or metastasis.

II.2 Determining Reportability
✓ Added first coding instruction: Use this list as a reference of last resort.
✓ Added coding instruction to clarify modifying words used with ambiguous terms. Basically, ignore the modifier and accept the reportable ambiguous term.

II.2.2 Ambiguous Diagnostic Reportable Terms
✓ Updated guideline to reference ICD-O-3.2 rather than ICD-O-3.

II.2.5 Benign/Borderline Brain and CNS Tumors
✓ Updated instruction for juvenile astrocytomas/pilocytic astrocytomas reported as 9421/3 to include "primary site is C71_."
✓ Added exception to the instruction above:
  Exception: The behavior is non-malignant when the primary site is optic nerve, C723.

II.2.5.1 Date of Diagnosis for Benign/Borderline Brain and CNS Tumors
- ✓ Added instruction for non-analytic cases:
  - ➢ For **non-analytic** cases (Class of Case 30-99): All attempts should be made to determine or estimate the date/year of diagnosis.
    - ▪ If no information about the date or at least year of diagnosis is available:
      - • Use the date of admission /1st contact and apply the applicable coding instructions.

II.2.5.3 WHO Grade - Benign and Borderline Brain and CNS Tumors
- ✓ Moved WHO Classifications to new Guidelines section.
- ✓ Added coding instruction references for when WHO Grade is not documented for non-malignant Brain and CNS tumors.
  - ➢ AJCC Chapter 72, Table 72.2.
  - ➢ Solid Tumor Rules, Non-Malignant CNS Tumors - WHO Grades of Select Neoplasms.

II.3 Abstracting - Accession and Sequence Number
- ✓ Expanded last sentence to clarify that the sequence number is different "for each new tumor."

III.2.1 Name
- ✓ Replaced instructions for maiden name with birth surname.

III.2.1.1 Entering Names
- ✓ Replaced instructions for maiden name with birth surname.
- ✓ Added note to explain that birth surname is a gender-neutral replacement for the maiden name data item.

III.2.2 Medical Record Number
- ✓ Removed coding instruction for alternate medical record number. No such data item listed in the NAACCR Data Dictionary.

III.2.8 Sex
- ✓ Codes 5 and 6 - Added instruction and priority order for coding.

III.2.10 Race and Ethnicity
- ✓ Added coding instruction for using parent's race to code the data item.

III.2.10.1 Codes for Race Data Item - *Renamed*
- ✓ Renamed page to Codes for Race Data Item (from Codes for Race Field).

III.2.10.2 Spanish/Hispanic Origin
- ✓ Replaced instructions for maiden name with birth surname.
- ✓ Updated coding instructions to align with standard setters.
- ✓ Replaced maiden name with birth surname in codes table.

III.2.12 Age at Diagnosis
- ✓ Updated description to clarify that this data item is tumor specific and that the patient can be a different age for each tumor diagnosis.

III.3.3 Date of Diagnosis
- ✓ Added instruction for non-analytic cases:
  - ➢ For **non-analytic** cases (Class of Case 30-99): All attempts should be made to determine or estimate the date/year of diagnosis.
    - ▪ If no information about the date or at least year of diagnosis is available:
      - • Use the date of admission /1st contact and apply the applicable coding instructions.

III.3.9 Payment Source (Primary and Secondary)
- ✓ Codes 02 and 10, added coding instructions not previously included in Volume I, to align with standard setters.
- ✓ Code 60 description updated:
  - ➢ Change age from 62 to 65.
  - ➢ Added "or are dialysis patients."

III.3.16 Discovered by Screening
- ✓ Added coding instructions section.
  - ➢ Separated coding instruction from data item description and added them to new coding instructions section.

IV.1.6 Text - Pathology Findings
- ✓ Updated data item description to define pathology only consultation cases.
- ✓ Added CCR recommendation that information from consult pathology reports be preferred over the original pathology report.

IV.2 Diagnostic Confirmation
- ✓ Added coding instructions not previously included in Volume I, to align with standard setters.
- ✓ Added instructions for when to change the diagnostic confirmation to a lower code.
- ✓ Code 5 - Instruction updated to clarify the use of code 5 when there is no other diagnostic workup.

IV.3 COVID-19 - *New Page*
- ✓ New introduction page provides coding overview for data collection of the new COVID-19 data items for cases diagnosed January 1, 2021 and forward.

IV.3.1 NCDB - SARSCoV2 - Test - *New Page*
- ✓ New page provides coding instructions for data collection of NCDB - SARSCoV2 - Test data item for cases diagnosed January 1, 2021 and forward.

IV.3.2 NCDB - SARSCoV2 - Pos *New Page*
- ✓ New page provides coding instructions for data collection of NCDB - SARSCoV2 - Pos data item for cases diagnosed January 1, 2021 and forward.

IV.3.3 NCBD - SARSCoV2 - Pos Date - *New Page*
- ✓ New page provides coding instructions for data collection of NCBD - SARSCoV2 - Pos Date data item for cases diagnosed January 1, 2021 and forward.

IV.3.4 NCDB - SARSCoV2 - TX Impact - *New Page*
- ✓ New page provides coding instructions for data collection of NCDB - SARSCoV2 - TX Impact data item for cases diagnosed January 1, 2021 and forward.

V.1 Primary Site
- ✓ Updated resource to reference ICD-O-3.2 rather than ICD-O-3.
- ✓ Added GIST to instruction on coding site of origination.
- ✓ Added C449 for Merkel cell in nodal or distant site when the site of origin is unknown.
- ✓ Updated section on coding Occult Head and neck.
- ✓ Added the following Primary Site/Site Codes to codes table:
    - ➢ Ampullary/peri-ampullary   C241
    - ➢ Clavicular skin   C445
    - ➢ Gastrohepatic ligament   C481
    - ➢ Genu of pancreas   C250
    - ➢ Interhemispheric fissure (cerebrum)   C710
    - ➢ Lateral tongue   C023
    - ➢ Uncinate of pancreas   C250

V.1.3 Primary Site - Site Specific Special Conditions
- ✓ Added coding instruction to code the site for where the bulk of the tumor is or where the epicenter is. Do not code C448.
- ✓ Added section for Angiosarcoma.

V.3 ICD-O Morphology - Histology and Behavior
- ✓ Updated description for the 2021 ICD-O-3.2 histology coding changes.
- ✓ Updated reminder and order of resources to be used when coding histology.

V.3.1 Histologic Type
- ✓ Updated resource to reference ICD-O-3.2 rather than ICD-O-3.

V.3.3 Behavior
- ✓ Removed GIST example for when using /3 on in-situ. All GIST are now coded as /3 for cases diagnosed January 1, 2021 and forward.

V.4 Grade and Differentiation
- ✓ Updated bullet 1 to list the four data items (from three).
- ✓ Added new data item, Grade Post Therapy Clin (yc).
- ✓ Renamed to Grade Post Therapy Path (yp) (from Grade Post Therapy).
- ✓ Added dates of requirement next to data item in list.
- ✓ Added bullet that describes the requirements of all four grade data items:
    - ➢ Grade is coded in separate, specific data items as follows:
        - ▪ Grade Clinical (2018 +)
        - ▪ Grade Pathological (2018 +)

- ▪ Grade Post Therapy Clin (yc) (2021 +)
- ▪ Grade Post Therapy Path (yp) (2018 +)

V.4.1 Grade - General Instructions
- ✓ Updated description to include the requirements of all four grade data items.
- ✓ Added new data item, Grade Post Therapy Clin (yc).
- ✓ Renamed to Grade Post Therapy Path (yp) (from Grade Post Therapy).

V.4.1.1 Grade - Clinical
- ✓ Added instruction describing priority coding of grade when multiple tumors present and abstracted as one primary.
- ✓ Renamed to Grade Post Therapy Path (yp) (from Grade Post Therapy).

V.4.1.2 Grade - Pathological
- ✓ Added instruction describing priority coding of grade when multiple tumors present and abstracted as one primary.
- ✓ Renamed to Grade Post Therapy Path (yp) (from Grade Post Therapy).

V.4.1.3 Grade - Post Therapy Clin (yc) - *New Page*
- ✓ New page provides coding instructions for data collection of Grade - Post Therapy Clin (yc) data item on cases diagnosed January 1, 2021 and forward.

V.4.1.4 Grade - Post Therapy Path (yp) (from V.4.1.3) - *Renamed*
- ✓ Renamed page to Grade Post Therapy Path (yp) (from Grade Post Therapy).
- ✓ Added instruction describing priority coding of grade when multiple tumors present and abstracted as one primary.
- ✓ Code 9 - Instruction added for surgical resection done after neoadjuvant therapy with no residual tumor.

V.5.1 Tumor Size Clinical
- ✓ Added date of CCR requirement for cases diagnosed January 1, 2016 forward to the description for consistency.
- ✓ Added priority order for coding clinical tumor size:
    1. Operative report
    2. Image-guided tissue biopsy
    3. Diagnostic imaging
    4. Physical exam
- ✓ Added and reordered multiple coding instructions to clarify data item coding and to align with standard setters.
- ✓ Code 000 - Added coding instructions.
- ✓ Code 999 - Updated coding instructions and changed list from site/histology to Schema ID/Schema Name.

V.5.2 Tumor Size Pathologic - *Renamed*
- ✓ Renamed page to Tumor Size Pathologic (from Tumor Size Pathological) to match standard setter's.
- ✓ Added date of CCR requirement for cases diagnosed January 1, 2016 forward to the description for

consistency.
- ✓ Added and reordered multiple coding instructions that were not previously included in Volume I, to align with standard setters.
  - ➢ Code 000 - Added coding instructions
  - ➢ Code 999 - Updated coding instructions and changed list from site/histology to Schema ID/Schema Name.

V.5.3 Tumor Size Summary
- ✓ Added date of CCR requirement for cases diagnosed January 1, 2016 forward to the description for consistency.
- ✓ Code 999 - Updated coding instructions and changed list from site/histology to Schema ID/Schema Name.

V.6 Mets at Diagnosis Bone, Brain, Liver, Lung, Distant Lymph Nodes, and Other
- ✓ Removed sub-bullet for lymphoma of all sites, with histology codes and added into sub-pages below as Schema ID/Schema Name listing.

V.6.1 Mets at Diagnosis - Bone
V.6.2 Mets at Diagnosis - Brain
V.6.3 Mets at Diagnosis - Liver
V.6.4 Mets at Diagnosis - Lung
V.6.5 Mets at Diagnosis - Distant Lymph Nodes
V.6.6 Mets at Diagnosis - Other
- ✓ Updated sub-bullets of 5th bullet that instructs on coding involvement to list hematopoietic inclusion in Schema ID/Schema Name order.
- ✓ Code 0 - Added sub-bullet for coding the tumor behaviors benign /0, borderline /1, or in-situ /2.
- ✓ Code 8 - Revisions:
  - ➢ Rewrote instruction to remove site/histology inclusion tables.
  - ➢ Added site codes C770-C779.
  - ➢ Removed 00821 Plasma Cell Myeloma and 00830 HemeRetic.
- ✓ Added link to SEER Appendix A for additional information on Schema and Schema ID.

V.7 Lymphovascular Invasion
- ✓ Revised neoadjuvant coding instruction to "Use the table below for cases treated with neoadjuvant (preoperative) therapy. Code LVI based on the medical record when medical record conflicts with this table."
- ✓ Code 8 - Revisions:
  - ➢ Removed sub-bullet "Schemas other than Penis 00570 and Testis 00590 if the registry has opted not to collect" because the CCR requires if available for all sites.
  - ➢ Updated list of Schema ID/Schema Names to be coded to code 8.
    - ▪ 00430 GIST
    - ▪ 00830 HemeRetic
    - ▪ 00790 Lymphoma
    - ▪ 00795 Lymphoma (CLL/SLL)
    - ▪ 00710 Lymphoma Ocular Adnexa
    - ▪ 00811 Mycosis Fungoides (MF)
    - ▪ 00822 Plasma Cell Disorder

- 00821 Plasma Cell Myeloma
- 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
✓ Code 9 - Added instruction to code to 9 when there is no information/documentation from the pathology report or other sources.

V.8 Terms Indicating In-situ for Staging
✓ Added site and/or histology codes.

V.9 Stage at Diagnosis
✓ Added link to Appendix Q.
  ➢ A new section for additional staging information related to Site-Specific Data Items (SSDIs) has been added to Appendix Q.

V.9.1 Staging Requirements - *Renamed*
✓ Renamed page to Staging Requirements (from Staging Requirements 2014-2018) to be static going forward.
✓ Updated description to indicate "changes over the last few years" rather than "the past four years."
✓ Updated Staging Requirements Table:
  ➢ Added 2021 Requirements to the Staging Requirements table.
  ➢ Removed requirements prior to 2018 and added a link to where achieved Volume I documents are located on the CCR website.
  ➢ Added AJCC TNM Cervix 9th Version to the table. Important information regarding AJCC TNM Cervix 9th Version:
    - Used for Cervix primary **only**.
    - Coding is to be done in the AJCC TNM Edition Number data item.

V.10 AJCC TNM Staging - *Renamed*
✓ Renamed page to AJCC TNM Staging (from AJCC 8th Edition) to be static going forward.
✓ Added guidelines section.
  ➢ Moved links to AJCC Cancer Staging Manual and to CAnswer Forum into guidelines.

V.10.1 AJCC TNM Staging General Information
✓ Added new AJCC TNM Post Therapy Clin (yc) data item.
✓ Renamed to Grade Post Therapy Path (yp) (from Grade Post Therapy).
✓ Added bullets that describe the requirements of all four data items as follows:
The CCR requires AJCC TNM Staging by CoC-accredited facilities for:
  ➢ AJCC TNM Clinical and Pathologic stage for all cases diagnosed January 1, 2018 and forward.
  ➢ AJCC TNM Post Therapy Path (yp) stage (renamed from AJCC TNM Post Therapy) for cases diagnosed January 1, 2018 and forward.
  ➢ AJCC TNM Post Therapy Clin (yc) stage for cases diagnosed January 1, 2021 and forward.
✓ Added tables for each of the AJCC TNM Stage classifications and the data items included for each.

V.10.1.1 AJCC TNM Clinical - *Deleted*
V.10.1.2 AJCC TNM Pathological - *Deleted*
V.10.1.3 AJCC TNM Post Therapy - *Deleted*
✓ Pages **deleted** because only CoC facilities are required to collect these data items. Therefore, the

decision was made that our instruction should not potentially conflict with the CoC.

V.10.2 AJCC TNM Edition Number
✓ Added AJCC TNM Cervix 9th Version information to the data item to explain AJCCs change from Editions to Versions.
✓ Important information regarding AJCC TNM Cervix 9th Version:
  ➢ Used for Cervix primary **only**.
  ➢ Coding is to be done in the AJCC TNM Edition Number data item.
✓ Code 09 (codes table) - Added 09 Ninth edition (currently for cervix cases only).

V.11.1 Extent of Disease (EOD)
✓ Added guidelines section.
  ➢ Moved links to Extent of Disease 2018 General Instructions and to CAnswer Forum into guidelines section.

V.11.1.1 EOD - Primary Tumor
✓ Updated the description paragraph to include "at diagnosis."
✓ Added coding instructions to clarify when to code clinical vs pathological.
✓ Added additional instruction for coding this data item using clinical information when the patient had neoadjuvant therapy and the clinical and pathological information are the same.
✓ Added a note to coding instruction for in-situ tumors with nodal metastatic involvement to clarify that the tumor should be coded to behavior /3.
✓ Code 800 - Added the following note:
  Note: This does not apply to those cases where a biopsy removes all of the tumor and there is not residual tumor on the surgical resection.

  ➢ When *EOD-Primary Tumor* is coded to 800:
    ▪ *Tumor Size Clinical* should be coded to 000 when there is no surgical resection for the primary tumor or site, but clinically no primary tumor was identified.
    ▪ *Tumor Size Pathologic* should be coded to 000 when the suspected tumor or site is resected, but no tumor is found. If surgical resection is done, code 999.

V.11.1.2 EOD - Regional Nodes
✓ Added coding instructions to clarify when to code clinical vs pathological.
✓ Code 00 - Additions:
  ➢ Added clarifying bullet specific to breast and thyroid lymph node involvement for in-situ behavior /2 tumors.
  ➢ Added a note to coding instruction for in-situ tumors with nodal metastatic involvement to clarify that the tumor should be coded to behavior /3.
✓ Code 888 - Updated coding instructions and changed list to Schema ID/Name order from site/histology order.
✓ Code 800 (codes table) - Added Lymph node(s), NOS to description in codes table.

V.11.1.3 EOD - Mets
✓ Added the following exception to coding instruction for when pathological findings take priority over clinical findings:

Exception: Not every metastatic site may be biopsied; however, for purposes of coding this data item, each metastatic site, whether confirmed clinically or pathologically, should be included, which may mean that clinical evidence would take priority over pathological.
- ✓ Added additional instruction for coding this data item using clinical information when the patient had neoadjuvant therapy and the clinical and pathological information are the same.
- ✓ Added a note to coding instruction for in-situ tumors with nodal metastatic involvement to clarify that the tumor should be coded to behavior /3.
- ✓ Code 88 - Updated coding instructions and changed list to Schema ID/Name order from site/histology order.

V.11.2 EOD Prostate Pathological Extension - *Renamed*
- ✓ Renamed page to EOD Prostate Pathological Extension (from EOD – Prostate Pathological Extension) to match standard setters.

V.13 SEER Site-Specific Factor 1
- ✓ Updated list of Schema ID/Sites that the data item applies to.
- ✓ Code 9 (codes table) - Updated to include "Not documented in medical record," and 'Not performed, or unknown if assessed."

V.15 Summary Stage 2018 (SS2018)
- ✓ Added guidelines section.
  - ➤ Moved links to Summary Stage 2018 Manual and to Ask a SEER Registrar into guidelines section.
  - ➤ Added Summary Stage Coding Guide instruction and table to direct registrars to the correct **data item** (and corresponding manual).

VI.1.2 First Course of Treatment - Data Entry
- ✓ Added priority order for entering text documentation.
- ✓ Added coding instructions for documenting first course of therapy (treatment plan) from the medical record, definition, and exception.
- ✓ Added coding instruction: Do not count *Scope of Lymph Node Surgery* code 1 as surgery for the purpose of coding this data item.

VI.1.3 Neoadjuvant Treatment - First Course of Therapy - *New Page*
- ✓ New page provides general guidelines for data collection of the three new Neoadjuvant data items being collected for cases diagnosed January 1, 2021 and forward.

VI.1.3.1 Neoadjuvant Therapy - *New Page*
- ✓ New page provides coding instructions for data collection of Neoadjuvant Therapy data item for cases diagnosed January 1, 2021 and forward.

VI.1.3.2 Neoadjuvant Therapy - Clinical Response - *New Page*
- ✓ New page provides coding instructions for data collection of Neoadjuvant Therapy - Treatment Response data item for cases diagnosed January 1, 2021 and forward.

VI.1.3.3 Neoadjuvant Therapy - Treatment Effect - *New Page*
- ✓ New page provides coding instructions for data collection of Neoadjuvant Therapy - Treatment

Effect data item for cases diagnosed January 1, 2021 and forward.

VI.2.4 Surgery of Primary Site
- ✓ Added coding instruction to clarify when operative report takes precedence over the pathology report.
- ✓ Codes 00, 98, and 99 - Added coding instructions that were not previously included in Volume I, to align with standard setters.

VI.2.4.1 Date of Surgery
- ✓ Added coding instruction: Do not count *Scope of Lymph Node Surgery* code 1 as surgery for the purpose of coding this data item.

VI.2.4.2 Surgical Margins of the Primary Site
- ✓ Added coding instructions for code 0 that was not previously included in Volume I, to align with standard setters.
- ✓ Revised coding instructions for code 9 to include the following instructions:
  - ➢ When *Surgery of Primary Site* is coded to 98.
  - ➢ Primary site is C420, C421, C423, C424, C760-C768, C770-C779, or C809.
  - ➢ Not documented, unknown if surgical procedure of the primary site has been performed.
  - ➢ Death Certificate Only (DCO).

VI.2.5.1 Date of Sentinel Lymph Node Biopsy
- ✓ Added coding instruction to clarify the data item may be left blank:
  - ➢ SLNBx attempted but "failed to map."
  - ➢ Cases other than breast or cutaneous melanoma.

VI.2.5.1.1 Date of Sentinel Lymph Node Biopsy Flag
- ✓ Code 11 (codes table) - Added SLNBx attempted but "failed to map" and "Cases other than breast or cutaneous melanoma."

VI.2.5.2 Sentinel Lymph Nodes Positive
- ✓ Added coding instruction to clarify the data item may be left blank for cases other than breast and cutaneous melanoma.
- ✓ Breast carcinoma coding instructions update/addition
  - ➢ Second sub-bullet, for clarification removed "but the number is unspecified."
  - ➢ Third sub-bullet was added:
    - ▪ The CAP Protocol for Breast is designed to capture information from the resection (there is no diagnostic protocol for breast). As a result, when the sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, only the overall total number of positive regional nodes (both sentinel and regional) is recorded. The number of sentinel nodes is not captured.

VI.2.5.3 Sentinel Lymph Nodes Examined
- ✓ Added coding instruction to clarify the data item may be left blank for cases other than breast and cutaneous melanoma.

VI.2.6 Scope of Regional Lymph Node Surgery
- ✓ Added and reordered multiple coding instructions to align with standard setters.
- ✓ Added link to Appendix A - Terms and Definitions.
- ✓ Added priority order for coding when there is a discrepancy regarding he number of positive lymph nodes.
- ✓ Separated coding instructions and codes table for breast and moved to the end of the document in order to remain ADA compliant.
- ✓ Added instruction to not default to code 9 when site is occult head and neck with positive lymph nodes.
- ✓ Code 9 - Added instructions for code 9 to align with standard setters.

VI.2.6.1 Date of Regional Lymph Node Dissection
- ✓ Added "cutaneous" to breast and melanoma specific coding instruction header.
- ✓ Added coding instruction to direct to leave *Date Regional Lymph Node Dissection* blank when **only** a sentinel lymph node biopsy is performed.

VI.2.6.2 Regional Lymph Nodes Positive
- ✓ Added instruction to include lymph nodes that are regional in the current AJCC Staging or EOD 2018 Manuals.
- ✓ Added instruction on recording the lymph nodes removed during an autopsy for autopsy only cases.
- ✓ Expanded instruction on priority order for synoptic report to clarify the use of the CAP protocol.
- ✓ Code 99 - Updated coding instructions and changed list to Schema ID/Name order from site/histology order.

VI.2.6.3 Regional Lymph Nodes Examined
- ✓ Added instruction to include lymph nodes that are regional in the current AJCC Staging or EOD 2018 Manuals.
- ✓ Added instruction on recording the lymph nodes removed during an autopsy for autopsy only cases.
- ✓ Expanded instruction on priority order for synoptic report to clarify the use of the CAP protocol.
- ✓ Code 97 -Added clarifying sentence to last bullet indicating the removal of lymph nodes during autopsy is a dissection.
- ✓ Code 99 - Updated coding instructions and changed list to Schema ID/Name order from site/histology order.

VI.2.8 Surgery of Other Regional Sites, Distant Sites, or Distant Lymph Nodes
- ✓ Added and reordered multiple coding instructions to align with standard setters.
- ✓ Codes 0 and 9 - Added coding instructions not previously included in Volume I, to align with standard setters.
- ✓ Code 1 - Updated coding instruction to reference the site codes rather than the description of the site.
- ✓ Codes 2 and 4 - Updated instructions to include definitions based on the current AJCC Staging Manual or EOD 2018 for regional (code 2) verses distant (code 4).

VI.2.10 Systemic Therapy with Surgery Sequence
- ✓ Added note to define surgery for the purposes of coding this item.
- ✓ Added coding instruction: Do not count *Scope of Lymph Node Surgery* code 1 as surgery for the purpose of coding this data item.

VI.2.11 Reason for No Surgery of the Primary Site
- ✓ Added and reordered multiple coding instructions to align with standard setters.
- ✓ Code 1 change - Code 1 when *Surgery of the Primary Site* is coded 98 (not applicable).

VI.3.3.1 Radiation Primary Treatment Volume - Phases I-III
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.
- ✓ Code 00 - Added coding instruction for coding to 00 in phase II and/or III items, when the patient receives just one and/or two phase(s) of treatment.
- ✓ Code 98 - Added coding instruction for coding radioisotope treatment I-131 for thyroid cancer cells in the body, since there is no specific anatomical treatment volume involved.
Note: Code 93 has been reserved for whole body treatment with external beam radiation such as is done prior to bone marrow transplantation.

VI.3.3.2 Radiation to Draining Lymph Nodes - Phases I-III
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.

VI.3.3.3 Radiation Treatment Modality - Phases I-III - *New Code*
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.
- ✓ Code 13 - Updated to differentiate code for Yttrium for cases 1/1/2018 + and code 07 for cases prior to 1/1/2018.
- ✓ Added "or 12" to instruction indicating that this data item should be coded if external beam codes are coded to 01-06, or 12.
- ✓ Added link to STORE Appendix B - Coding Modality for the Heavy Equipment of Modern Radiation Therapy.
- ✓ Code 98 - *New Code* (codes table) - Radiation therapy administered; modality unknown.
- ✓ Code 99 (codes table) - Removed "Treatment radiation modality unknown."

VI.3.3.4 Radiation External Beam Planning Technique - Phases I-III
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.
- ✓ Added link to STORE Manual and CTR Guide to coding Radiation Therapy in STORE.

VI.3.3.5 Dose per Fraction - Phases I-III
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.
- ✓ Added instruction: Code the **actual** cGy if available when brachytherapy was administered to the patient (codes 07-12) for Phase I, II, III *Radiation Treatment Modality*.
  - ➤ If the dose is not available/provided in cGy for a brachytherapy procedure, code 99999.
- ✓ Code 99998 - Updated to code to 99998 when radioisotopes were administered to patient (codes 13-16) for Phase I, II, or III *Radiation Treatment Modality*.

VI.3.3.6 Number of Fractions - Phases I-III
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.

VI.3.3.7 Total Dose - Individual Phases I-III
- ✓ Removed instruction "A new phase begins when there is a clinically meaningful change in the target volume, fraction size, modality, or treatment technique" to align with standard setters.
- ✓ Added instruction: Code the **actual** cGy if available when brachytherapy was administered to the patient (codes 07-12) for Phase I, II, III *Radiation Treatment Modality*.
  - ➤ If the dose is not available/provided in cGy for a brachytherapy procedure, code 99999.
- ✓ Code 99998 - Updated to code 99998 when radioisotopes were administered to patient (codes 13-16) for Phase I, II, or III *Radiation Treatment Modality*.

VI.3.5 Radiation Total Dose - Phases Combined - *Renamed*
- ✓ Renamed page to Radiation Total Dose - Phases Combined (from Total Dose - Phases Combined) for consistency.
- ✓ Added instruction: Code the **actual** cGy if available when brachytherapy was administered to the patient (codes 07-12) for Phase I, II, III *Radiation Treatment Modality*.
  - ➤ If the dose is not available/provided in cGy for a brachytherapy procedure, code 999999.
- ✓ Code 999998 - Updated to code 999998 when radioisotopes were administered to patient (codes 13-16) for Phase I, II, or III *Radiation Treatment Modality*.
- ✓ Code 999998 (code table) - Added "or the patient was treated with mixed modalities (e.g. external beam brachytherapy)" to code description.

VI.3.6 Radiation - Regional RX Modality - *Deleted*
VI.3.7 Radiation - RX Summ Radiation - *Deleted*
- ✓ Page **deleted** because they represented pre-2018 radiation coding. See Archived Volume I - Use case year of diagnosis to determine which Volume I to choose.
- ✓ As a result of the deleted pages, the following pages have been renumbered to:
  - ➤ **VI.3.6 Radiation Sequence with Surgery (from VI.3.8)**
    - ▪ Added note to define surgery for the purposes of coding this item.
    - ▪ Added coding instruction: Do not count *Scope of Lymph Node Surgery* code 1 as surgery for the purpose of coding this data item.
  - ➤ **VI.3.7 Radiation Treatment Discontinued Early (from VI.3.9)**
  - ➤ **VI.3.8 Location of Radiation Treatment (from VI.3.10)**
  - ➤ **VI.3.9 Reason for No Radiation (from VI.3.11)**

VI.7.2 Transplant/Endocrine Procedures
- ✓ Codes 11 and 12 - Added coding instruction to clarify priority order.
  - ➤ Codes 11 (bone marrow transplant autologous) and 12 (Bone marrow transplant allogenic) take priority over code 10 (BMT, NOS).

VI.8 Other Therapy - First Course of Treatment
- ✓ Added instruction for new modality of treatment named: **Optune** for treating Glioblastoma Multiforme (GBM).
- ✓ Removed date of diagnosis criteria from instruction referring users to the SEER Hematopoietic and Lymphoid Neoplasm Data base.

VI.8.2 Other Treatment Codes
- ✓ Code 1 (codes table) - Added Peptide Receptor Radionuclide Therapy (PRRT).

VI.9 RX Summary - Treatment Status
- ✓ Added coding instructions for the following codes to align with standard setters:
  - ➢ Code 0 - The patient does not receive **any** treatment.
    Note: Scope of Regional Lymph Node Surgery may be coded to 0, 1-7, or 9.
  - ➢ Do not count Scope of Lymph Node Surgery code 1 as surgery for the purpose of coding this data item.
  - ➢ Code 1 - Coding instructions, updated the following data items listed.
    - ▪ Changed field name "Radiation" to "Radiation Treatment Modality, Phase I, II, III."
    - ▪ Removed Scope of Regional Lymph node surgery from list.
  - ➢ Code 2 - Active surveillance/watchful waiting/deferred therapy, or any other similar options are recorded in the medical record.
  - ➢ Code 9 - Death Certificate Only (DCO) cases.

VII.2.11 Date of First Recurrence - *Renamed*
- ✓ Renamed page to Date of First Recurrence (from Recurrence Information) to remain consistent with other data items.
- ✓ Page provides coding instructions for data collection of Date of First Recurrence data item for cases diagnosed January 1, 2021 and forward.

VII.2.11.1 Date of First Recurrence Flag - *New Page*
- ✓ New page provides coding instructions for data collection of Date of First Recurrence Flag data item for cases transmitted January 1, 2021 and forward.
- ✓ New page added for flag field to be consistent with other date/date flag data items.

VII.2.11.2 Type of First Recurrence - *New Page*
- ✓ New page provides coding instructions for data collection of Type of First Recurrence data item for cases transmitted January 1, 2021 and forward.

IX.1.2 Modified Record
- ✓ Removed modified record length due to XML file not having a record length. XML is being implemented with the 2021 data changes.
- ✓ Modified instruction to link to Volume II, Appendix A rather than Appendix B. Appendix B of Volume II has been merged into Appendix A.

CHANGES to APPENDICES

Appendix A - Terms and Definitions
- ✓ Added definitions for the following terms:
  - ➢ Adjuvant Therapy
  - ➢ Axillary Lymph Node Dissection
  - ➢ Lymph Node Dissection
  - ➢ Non-Mass Enhancement
  - ➢ Optune Treatment
  - ➢ Primary Treatment
  - ➢ Radical Lymph Node Dissection
  - ➢ Regional Lymph Node Dissection

- ➢ Surgical Resection
- ➢ Systemic Therapy
- ✓ Modified/augmented the following definitions:
  - ➢ Active surveillance - Added "Active Monitoring" as synonym
  - ➢ Neoadjuvant Therapy - Added additional text

Appendix C - Codes for Countries
- ✓ Modified C.1 Alphabetical list to align with standard setters.
- ✓ Modified C.2 Code Order list to align with standard setters.

Appendix G - Codes for Casefinding
- ✓ Updated with casefinding lists that are effective for cases diagnosed between October 1, 2020 and September 30, 2021.

Appendix H - Codes for California Counties
- ✓ Reformatted table to one column rather than two.
- ✓ Added a column for Region associated with the county.

Appendix J - Spanish Surnames
- ✓ Added description of data item and list.
- ✓ Reformatted table to include two columns that wrap rather than two or three depending on which letter of the alphabet you were looking at.

Appendix K - STORE-Surgery Codes
- ✓ Updated all site pages histology exclusions to (Except for M-9732, 9741-9742, 9761-9809, 9820, 9826, 9831-9834, 9840-9920, and 9931-9993) (from: M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).
- ✓ Bladder:
  - ➢ Updated SEER Notes for code 60 and 71.
  - ➢ Added additional SEER Note to code 71.
- ✓ Breast:
  - ➢ Added new SEER Note to Code 30.
- ✓ Colon:
  - ➢ Added two new general SEER Notes.
- ✓ Ovary:
  - ➢ Updated SEER Notes to start by saying "Also use" instead of "Use."
- ✓ Prostate:
  - ➢ Code 10 - Removed the words "or excision."
- ✓ Rectosigmoid:
  - ➢ Added new general SEER Note.
- ✓ Rectum:
  - ➢ Added new general SEER Notes.
- ✓ Skin:
  - ➢ Updated SEER Note located under code 25 to add "For Photodynamic therapy (PDT) as entry to note.

Appendix Q - Site Specific Data Items (SSDIs)

- ✓ Added note with link to Stage Related Data Items section added to the end of the page.
- ✓ Added Grade Post Therapy Clin (yc) and renamed Grade Post Therapy Path (yp) (from Grade Post Therapy).
- ✓ Updated instructions of how to read tables. Specifically, the SSDIs are organized alphabetically by" section. This update also includes the same updates to all tables throughout. The intent was to make this section simpler.
- ✓ Updated Coding Guidelines sub-bullet of second bullet to clarify that the codes 8, 9, and blank are allowable for SSDI's when they are not required by the CCR and it is an allowable value for the SSDI.
  - ➢ Revised to AJCC Chapter rather than AJCC ID.
  - ➢ Updated all tables to remove the columns:
    - ▪ AJCC ID
    - ▪ Schema ID Description
    - ▪ Site Codes
    - ▪ Histology Codes
- ✓ Updated instructions for requirement by CCR and COC and added a column to all tables to indicate when the SSDI was implemented.
- ✓ Renamed the following SSDIs:
  - ➢ Grade Post Therapy Path (yp) (from Grade Post Therapy)
  - ➢ LDH Lab Value (from LDH Pretreatment Lab Value)
  - ➢ LDH Level (from LDH Pretreatment Level)
- ✓ Added the following *new* SSDIs to the appropriate schemas:
  - ➢ ALK Rearrangement
    - ▪ 00360 Lung
  - ➢ BRAF Mutational Analysis
    - ▪ 00200 Colon and Rectum
  - ➢ CA19-9 Pretreatment Lab Value
    - ▪ 00280 Pancreas
  - ➢ EGFR Mutational Analysis
    - ▪ 00360 Lung
  - ➢ NRAS Mutational Analysis
    - ▪ 00200 Colon and Rectum
- ✓ Added the following *existing* SSDIs to *additional* appropriate schemas:
  - ➢ Ki-67
    - ▪ 00302 NET Ampulla of Vater
    - ▪ 00320 NET Appendix
    - ▪ 00330 NET Colon and Rectum
    - ▪ 00301 NET Duodenum
    - ▪ 00310 NET Jejunum and Ileum
    - ▪ 00340 NET Pancreas
    - ▪ 00290 NET Stomach
  - ➢ Her2 Overall Summary
    - ▪ 00161 Esophagus Squamous
    - ▪ 00169 Esophagus
    - ▪ 00170 Stomach
  - ➢ Schema Discriminator 2
    - ▪ 00421 Soft Tissue Abdomen and Thoracic
    - ▪ 00410 Soft Tissue Trunk and Extremities

          ▪ 00450 Soft Tissue Other
- ✓ New Section - Additional Stage-related Data Items - This section includes tables that list the requirement dates for Site-Specific Data Items required for staging for both 2018 and 2021 SSDIs.

Appendix R - Coding Resource
- ✓ Added new manuals and updated publication date of revised manuals.

Appendix S - Historical Coding and Staging Manual Requirements for CCR
- ✓ Added the 2018 SEER Program Manual and the 2018 STORE manual to the table.